Adrienne Graves

Dr. Graves is a neuroscientist by training and a global leader in the pharmaceutical and medical device industries. Dr. Graves held multiple positions at Santen Inc., including serving as the President and Chief Executive Officer from 2002 to 2010. In this role, Dr. Graves successfully established Santen Inc.’s global presence, brought multiple products through preclinical and clinical development to approval and commercialization, and led teams through successful acquisitions and partnerships. Prior to joining Santen Inc., Dr. Graves spent 9 years at Alcon Laboratories, Inc., where she progressed through various roles including Director of International Ophthalmology. Dr. Graves currently serves as an Independent Director on the boards of Akorn Inc., Nicox S.A., Surface Pharmaceuticals, and Oxurion Corporation. She previously held board positions at Encore Vision (2011 - 2017; acquired by Novartis), Envisia Therapeutics (2014 - 2017; assets acquired by Aerie Pharmaceuticals), TearLab Corporation (2005 - 2018), and Aerpio Therapeutics (2012 - 2017). Dr. Graves also serves as Director on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund.